Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.69 |
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | CD38 | P28907 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL684231 | 0.89 | RAB9A (0.76) | RAB9AHTTKDM4EMEN1LMNA | |
| SCHEMBL6571415 | 0.89 | RAB9A (0.76) | RAB9AHTTKDM4EMEN1LMNA | |
| SCHEMBL6571417 | 0.89 | RAB9A (0.76) | RAB9AHTTKDM4EMEN1LMNA | |
| SCHEMBL684230 | 0.88 | RAB9A (0.78) | RAB9AHTTKDM4EMEN1LMNA | |
| SCHEMBL684189 | 0.88 | NPC1 (0.64) | RAB9AHTTKDM4EMEN1LMNA | |
| SCHEMBL680226 | 0.87 | CD38 (0.61) | RAB9AHTTKDM4EMEN1LMNA | |
| SCHEMBL684185 | 0.87 | CD38 (0.61) | RAB9AHTTKDM4EMEN1LMNA | |
| SCHEMBL10053130 | 0.86 | RAB9A (0.60) | RAB9AHTTKDM4EMEN1LMNA | |
| SCHEMBL684636 | 0.84 | MAPT (0.70) | RAB9AHTTKDM4EMEN1LMNA | |
| SCHEMBL14949043 | 0.83 | MAPT (0.78) | RAB9AHTTKDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906829-B2 | Synergistic algicidal compositions including hydrazone derivatives and copper | DOW AGROSCIENCES LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-8715745-B2 | Fungicidal compositions including hydrazone derivatives and copper | DOW AGROSCIENCES, LLC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8715745-B2 | Fungicidal compositions including hydrazone derivatives and copper | DOW AGROSCIENCES, LLC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120010075-A1 | SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | DOW AGROSCIENCES LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009274-A1 | FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | DOW AGROSCIENCES LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009274-A1 | FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | DOW AGROSCIENCES LLC (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010075-A1 | SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | SOD1, CYP51A1, SOD3 | RAB9A 3846/4885HTT 386/4885KDM4E 1473/4885 |
| US-20120009274-A1 | FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER | SOD1, CYP51A1, CYP4Z1 | RAB9A 3616/4885HTT 210/4885KDM4E 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.